Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients

Patients must meet the following criteria in order to be included in the research study:

• Histologically or cytologically confirmed diagnosis of advanced or metastatic solid tumors that are not responsive to standard therapies or for which there is no effective therapy.
• At least 2 weeks or 5 half-lives, whichever is shorter, must have elapsed after prior chemotherapy or small molecule targeted therapy, respectively, at the time of the start of midazolam administration.
• Eastern Cooperative Oncology Group (ECOG) Performance Status score of ≤1.
• Adequate hematologic, liver and renal function.
• Ability to understand the nature of this study and give written informed consent.

Patients who meet any of the following criteria will be excluded from study entry:

• Participation in another therapeutic clinical trial within 28 days prior to start of midazolam administration.
• Prior treatment with entrectinib.
• Known hypersensitivity or intolerance to midazolam or oral formulation excipients, including allergy to cherries.
• Any condition (in the past 3 months) that may interfere with the conduct of study assessments or may interfere with the interpretation of study results.
• History of non-pharmacologically induced prolonged QTc interval (e.g., repeated demonstration of a QTc interval > 500 milliseconds from ECGs).
• Known active infections that may interfere with the conduct of study assessments or may interfere with the interpretation of study results (bacterial, fungal, or viral, including human immunodeficiency virus positive).
• Other Protocol defined Inclusion/Exclusion criteria apply.